Novavax (NVAX) Receives Price Target

Novavax (NVAX) : 5 investment research analysts covering Novavax (NVAX) have an average price target of $12.98 for the near short term. The highest target price given by the Brokerage Firm to the stock is $17 and the lowest target is $6 for the short term. Analysts expect the variance to be within $4.24 of the average price.

Novavax (NVAX) : Zacks Investment Research ranks Novavax (NVAX) as 4, which is a Sell recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.


Also, Equity Analysts at the Brokerage Firm, Citigroup, maintains their rating on the shares of Novavax (NASDAQ:NVAX). Citigroup has a Buy rating on the shares. As per the latest research report, the brokerage house raises the price target to $12 per share from a prior target of $10. The rating by the firm was issued on July 28, 2016.

Novavax (NASDAQ:NVAX): The stock opened at $6.85 on Thursday but the bulls could not build on the opening and the stock topped out at $6.89 for the day. The stock traded down to $6.71 during the day, due to lack of any buying support eventually closed down at $6.82 with a loss of -0.29% for the day. The stock had closed at $6.84 on the previous day. The total traded volume was 2,766,439 shares.

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.